774
Views
6
CrossRef citations to date
0
Altmetric
Conference and Workshop Reports

Burden and prevention of viral hepatitis in the Arctic region, Copenhagen, Denmark, 22–23 March 2012

, , , &
Article: 21163 | Published online: 17 Jul 2013

References

  • The Economist. June 16–22, 2012 issue, pp 13 and Special Report ‘The Vanishing North’, June 16th 2012. Available from: http://www.economist.com/printedition/2012-06-16.
  • Viral hepatitis: global policy. 2010
  • Atlantic interdisciplinary research network for social and behavioural issues in hepatitis C and HIV/AIDS: HIV/AIDS and hepatitis C: a scan of policies, programs, and research in Atlantic Canada. [cited 2012 Apr 3]. Available from: http://www.med.mun.ca/getdoc/beb4b9c6-72e4-4e66-ac24-1eab92856229/AIRN_Scan.aspx.
  • Chulanov V. Identification and management of chronic viral hepatitis in Russia, presented at VHPB meeting on Identification and management of persons with chronic viral hepatitis in Europe, Budapest, Hungary, 19 March 2010. 2011; 1911 Available from: http://www.vhpb.org/files/html/Meetings_and_publications/Viral_Hepatitis_Newsletters/vhv19n1.pdf Viral hepatitis 19n1 [serial on the Internet]..
  • Raczniak GA, Bulkow LR, Bruce MG, Zanis CL, Baum RL, Snowball MM, etal. Long-term immunogenicity of hepatitis A virus vaccine in Alaska 17 years after initial childhood series. J Infect Dis. 2013; 207: 493–6.
  • Sharapov UM, Bulkow LR, Negus SE, Spradling PR, Homan C, Drobeniuc J, etal. Persistence of hepatitis A vaccine induced seropositivity in infants and young children by maternal antibody status: 10-year follow-up. Hepatology. 2012; 56: 516–22.
  • Report VHPB meeting: ‘A completed schedule … enough to control HBV lifelong?’ Milan, Italy, 17–18 November 2012. Viral hepatitis 20n2 [serial on the Internet]. 2012;2. Available from: http://www.vhpb.org/files/html/Meetings_and_publications/Viral_Hepatitis_Newsletters/vhv20n2.pdf..
  • McMahon BJ, Bulkow LR, Singleton RJ, Williams J, Snowball M, Homan C, etal. Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program. Hepatology. 2011; 54: 801–7.
  • Krarup HB, Andersen S, Madsen PH, Okkels H, Hvingel BH, Laurberg P. Benign course of long-standing hepatitis B virus infection among Greenland Inuit?. Scand J Gastroenterol. 2008; 43: 334–43.
  • McMahon BJ. The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B. Hepatol Int. 2009; 3: 334–42.
  • Krarup H, Andersen S, Madsen PH, Christensen PB, Laursen AL, Bentzen-Petersen A, etal. HBeAg and not genotypes predicts viral load in patients with hepatitis B in Denmark: a nationwide cohort study. Scand J Gastroenterol. 2011; 46: 1484–91.
  • Minuk GY, Sun DF, Uhanova J, Zhang M, Caouette S, Nicolle LE, etal. Occult hepatitis B virus infection in a North American community-based population. J Hepatol. 2005; 42: 480–5.
  • Hansen N, Obel N, Christensen PB, Kjaer M, Laursen AL, Krarup HB, etal. Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: a Danish nationwide cohort study. BMC Infect Dis. 2011; 11: 177.
  • 2006. 13th International Congress on Circumpolar Health Gateway to the International Polar Year, Novosibirsk, Russia; June 12–16.
  • Minuk GY, Sun A, Sun DF, Uhanova J, Nicolle LE, Larke B, etal. Serological evidence of hepatitis E virus infection in an indigenous North American population. Can J Gastroenterol. 2007; 21: 439–42.
  • Borresen ML, Koch A, Biggar RJ, Ladefoged K, Melbye M, Wohlfahrt J, etal. Effectiveness of the targeted hepatitis B vaccination program in Greenland. Am J Public Health. 2012; 102(2): 277–84.